Skip to main content
Premium Trial:

Request an Annual Quote

Bush to Appoint Niederhuber as NCI Director; Sigma-Aldrich Names General Counsel; Gene Logic Fleshes Out Preclinical Division; and Others

President Bush intends to appoint John Niederhuber as the National Cancer Institute’s 13th director, the National Institutes of Health said this week in a statement.
 
Niederhuber was named acting director for the institute in June. He is also involved in research at the Laboratory of Tumor and Stem Cell Biology, part of the cell and cancer biology branch of NCI’s Center for Cancer Research. Niederhuber is also on the NIH Clinical Center’s medical staff.
 
Prior to becoming acting director, he was NCI's chief operating officer and deputy director for translational and clinical sciences. Prior to that he was chair of the National Cancer Advisory Board.
 
Niederhuber was a professor of surgery and oncology at the University of Wisconsin School of Medicine in Madison and director of the University of Wisconsin Comprehensive Cancer Center.
 
Niederhuber also chaired the department of surgery at Stanford University and was a professor at the Johns Hopkins University School of Medicine and at the University of Michigan

Rich Keffer joined Sigma-Aldrich as corporate vice-president, general counsel, and secretary, the company said Tuesday.
 
His appointment is effective Aug. 28.
 
Keffer comes to Sigma-Aldrich from D&K Healthcare, which was acquired by McKesson in 2005. He has 25 years of corporate legal experience from companies in the consumer products, chemical and pharmaceutical industries.
 
Keffer received his JD degree from Washington University School of Law and a BA in economics from Greenville College.  

Gene Logic named three new executives in its preclinical division’s toxicology services last week.
 
James R. Szabo was promoted to vice-president of toxicology services and C. Steven Godin was promoted to senior director of general toxicology.
 
Kory Engelke joined the company as senior director of general toxicology.
 
Prior to joining Gene Logic in 2004, Szabo was at Dow Chemical and lectured at the University of Houston. He was a research associate and teaching associate at the University of Illinois and had a private veterinary practice. He holds a D.V.M. and a Ph.D. in pathology from the University of Illinois.
 
Prior to joining Gene Logic in 2004, Godin was a senior study director at MPI Research, director of toxicology at White Eagle Toxicology Laboratories, manager of drug metabolism at Cephalon, and project scientist for ManTech Environmental. Godin holds a Ph.D. in pharmaceutical sciences from the University of Kentucky.
 
Engelke joined Gene Logic from Sucampo Pharmaceuticals. Prior to Sucampo, he was with Guilford Pharmaceuticals and Battelle Memorial Institute in the pharmaceutical product division. Engelke holds a Ph.D. in pharmacology from the University of Vermont and was a post-doctoral fellow at Battelle Pulmonary Therapeutics and Ohio State University.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.